Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three immunosuppressive and anti-inflammatory drugs: methylprednisolone, prednisone, and mycophenolate mofetil. Methylprednisolone and prednisone are synthetic glucocorticoid corticosteroids that suppress inflammation and modulate immune responses by binding to the glucocorticoid receptor (NR3C1), thereby inhibiting pro-inflammatory gene expression. Mycophenolate mofetil is an immunosuppressant prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), leading to reduced guanosine nucleotide synthesis required for lymphocyte proliferation. This combination is used in various autoimmune diseases (such as lupus nephritis), organ transplantation, retroperitoneal fibrosis, Graves’ orbitopathy, idiopathic thrombocytopenic purpura (ITP), and other conditions where strong immunosuppression is needed[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone + prednisone + mycophenolate mofetil.